Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly’s Thanksgiving Turkey: Lessons From Another Failed Alzheimer’s Program

Executive Summary

There was nothing to be thankful about from Lilly’s disclosure that its potential Alzheimer’s therapy solanezumab failed to demonstrate significant improvement in cognition in a third large Phase III trial. But it does reinforce the wisdom of FDA’s standards for subgroup analysis in failed trials.

Advertisement

Related Content

Looser Efficacy Standards Could Waste Taxpayer Dollars On Useless Drugs, NEJM Says
Lilly’s Failed Solanezumab: Could It Get Another Chance In A ‘Silicon Valley’ FDA?
US FDA Touts Value Of Phase III Trials Amid Presidential Transition
Acadia's Nuplazid Could Have The Alzheimer's R&D Curse
Lilly’s Solanezumab Fails, But The Surprise Would Have Been Success
Efficacy Signal For Lilly’s Solanezumab Stirs The Alzheimer’s Pot

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS119599

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel